Pharma channel feed

GSK joins Boehringer and As­traZeneca in cap­ping out-of-pock­et costs for in­halers

Last year

Medicare and Med­ic­aid open cov­er­age of an­ti-obe­si­ty drugs for heart pa­tients

Last year

Sen­ate opens probe in­to how high-risk re­search pos­es na­tion­al se­cu­ri­ty threats

Last year
China

Bay­er's re­struc­tur­ing hits phar­ma lead­er­ship, shift­ing about half of ex­ecs off top team

Last year
People

FDA ap­proves Idor­sia’s high blood pres­sure drug for pa­tients who need oth­er op­tions

Last year
FDA+

The Op­di­vo-Yer­voy com­bo from Bris­tol My­ers is work­ing to­ward ap­proval in first-line liv­er can­cer

Last year
R&D

As­traZeneca de­buts Air­supra DTC cam­paign along with a first-ever tele­health op­tion

Last year
Marketing

Lab­corp ex­pands Alzheimer’s blood tests for doc­tors and drug­mak­ers

Last year
R&D

Or­chard sets US price tag for rare dis­ease gene ther­a­py Len­meldy at $4.25M

Last year
Cell/Gene Tx

Non­prof­it tracks surge in med­ica­tion abor­tions as SCO­TUS gears up for hear­ing

Last year
Law

Sen­a­tors press De­part­ment of De­fense on over­re­liance on for­eign drug man­u­fac­tur­ers

Last year
FDA+
Manufacturing

Phar­ma com­pa­nies ques­tion new EU in­cen­tives as re­vamp ad­vances

Last year
Law

No­vo Nordisk bol­sters op­er­a­tions in Chi­na with $556M ex­pan­sion project

Last year
China
Manufacturing

FDA pro­pos­es tight­en­ing re­stric­tions on com­pound­ing three cat­e­gories of drugs

Last year
FDA+

Takeda's $5.2B Ari­ad deal pays off with a la­bel ex­pan­sion in rare form of leukemia

Last year

In Oprah’s TV spe­cial, We­govy and Zep­bound are the stars

Last year
Marketing

Mar­ket­ingRx roundup: Bris­tol My­ers en­lists Ted Dan­son for pso­ri­a­sis cam­paign; Re­gen­eron de­buts Eylea HD ef­fort

Last year
Marketing

As­traZeneca views $2B+ Fu­sion buy­out as ‘start­ing point’ for bet­ter ra­dio­phar­ma­ceu­ti­cals, com­bos

Last year
Deals

Study sug­gests con­tro­ver­sial patent re­view path­way is ef­fec­tive for bi­o­log­ics

Last year

Up­dat­ed: FDA ex­pands la­bel for nasal spray to treat chron­ic si­nus in­flam­ma­tion

Last year
FDA+

Ap­peals court re­vers­es No­var­tis win over Re­gen­eron in Eylea-Lu­cen­tis bat­tle

Last year
Law

FDA green­lights Or­chard's gene ther­a­py Len­meldy for rare and fa­tal dis­ease

Last year
Cell/Gene Tx
FDA+

Ex­act Sci­ences us­es March Mad­ness cam­paign to dri­ve colon can­cer screen­ing

Last year
Marketing

As­traZeneca joins Boehringer In­gel­heim in cap­ping out-of-pock­et in­haler costs at $35

Last year
First page Previous page 66676869707172 Next page Last page
A service from the Financial Times